Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
14
3
7
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
21%
3 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder
Role: lead
A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Orthopedic Surgery
Role: lead
A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery
Role: lead
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants
Role: lead
PK/PD Study of YZJ-1139
Role: lead
Safety and Efficacy Study of YZJ-1139 in Primary Chronic Insomnia Disorder
Role: lead
A Phase 1 Study of YZJ-4729 Tartrate Injection in Healthy Chinese Subjects
Role: lead
A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets
Role: lead
A Phase Ⅱ Study to Evaluate the Efficacy and Safety of YZJ-4729 in Patients With Moderate to Severe Acute Pain After Abdominal Surgery
Role: lead
Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment
Role: lead
Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment
Role: lead
A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects
Role: lead
Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder
Role: lead
A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors
Role: lead
All 14 trials loaded